Should You Buy Tesaro After Its Earnings Miss?

Tesaro just missed earnings estimates by $0.37 per share for its first quarter. Is this stock a bad news buy?

May 2, 2014 at 9:30AM

Tesaro (NASDAQ:TSRO), a development-stage biotech, reported its first-quarter earnings on April 30. Tesaro reported a net loss of $49.8 million, or $1.43 per share -- a steep drop from the loss of $18.9 million, or $0.66 per share, it posted in the prior-year quarter. Analysts polled by Thomson Reuters had expected a narrower loss of $1.06 per share.

Tesaro's two most advanced pipeline products are rolapitant, an orally and intravenously administered treatment for chemotherapy-induced nausea and vomiting (CINV), and niraparib, which is in late-stage trials for ovarian and breast cancer. Tesaro signed a marketing agreement with Opko Health (NYSE:OPK) for rolapitant in December 2010 and licensed niraparib from Merck (NYSE:MRK) in May 2012.

TSRO Chart

Source: YCharts.

Higher expenses, stagnant stock price
Tesaro attributed its wider quarterly loss to higher expenses across the board. Research and development expenses rose 70% year over year to $28.1 million, in addition to an in-process expense of $17 million for R&D related to a licensing and collaboration agreement with AnaptysBio in immuno-oncology antibodies.

Tesaro's general and adminstrative expenses climbed 96% to $4.7 million, due to higher non-cash stock-based compensation, a larger workforce, and professional service fees. Tesaro finished the quarter with $180 million in cash and equivalents.

Tesaro's lackluster earnings won't do much to boost the stock, which has slumped 9% over the past 12 months despite rising 78% over the past five years. Should investors invest in the stock while it hovers near 52-week lows or move on to more promising biotechs instead?

Near-term catalysts
Tesaro's nearest catalyst is its planned submission of a new drug application to the Food and Drug Administration for rolapitant in mid-2014. Rolapitant is currently in phase 3 trials for the oral indication and phase 2 trials for the IV one. If approved, analysts expect the drug to generate peak sales over $300 million.

However, there are a few issues with rolapitant that can't be ignored. Opko Health originally acquired rolapitant from Schering-Plough (now part of Merck) for $2 million in cash in 2009. But rather than start clinical trials, Opko simply held onto the drug and flipped it to Tesaro in 2010 in exchange for an up-front payment of $6 million and $115 million in additional milestone payments.

Although Opko made a quick profit on the deal, it wasn't clear why the company never tried to develop the drug. That question was likely answered last December, when Tesaro reported mixed results from two late-stage trials. Although rolapitant was effective at treating CINV during the 24- to 120-hour "delayed" period following chemotherapy, it did not significantly improve patients' conditions during the first 24 hours. It also failed to show significant improvement after 120 hours.

This means that rolapitant doesn't offer any clear advantages over Merck's Emend, a similar drug which prevents CINV for up to five days from when chemotherapy is administered. Merck reported that sales of Emend climbed 3.7% year over year to $507 million in fiscal 2013. Both rolapitant and Emend are NK-1 receptor antagonists, which block a substance in the brain that causes vomiting.

Don't overlook its immuno-oncology pipeline
Despite its problems with rolapitant, Tesaro could have a brighter future in cancer drugs. The company has initiated treatment in its phase 3 BRAVO study of niraparib for BRCA positive breast cancer, and is continuing enrollment in its phase 3 NOVA study of the drug for patients with high-grade serous, platinum-sensitive ovarian cancer.

It also plans to start enrolling patients in a phase 1 study of niraparib for patients with Ewing's sarcoma by mid-2014. Analysts expect niraparib to generate annual peak sales of more than $600 million if approved.

Niraparib could just be the beginning, however. Thanks to licensing agreements with Amgen, Merck, and Anaptysbio, Tesaro has built up an enviable pipeline of early-stage small molecule inhibitors and monospecific antibody candidates for the treatment of various tumors.

The Foolish takeaway
In conclusion, Tesaro has promising products in its long-term pipeline, but it's tough to recommend the stock, considering that its losses are widening, expenses are soaring, and rolapitant -- its best hope for revenue growth -- still faces significant challenges ahead. Investors might be better served by waiting on the sidelines and seeing what else transpires with the stock.

Will this stock be your next multibagger?
Give me five minutes and I'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks one stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year, his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252%, and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.

Leo Sun has no position in any stocks mentioned, and neither does The Motley Fool. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers